为您找到相关结果约497个

你是不是要搜索 期刊Dato-DXd 点击跳转

Datopotamab Deruxtecan (Dato-DXd) plus Durvalumab ± Carboplatin in Advanced/mNSCLC: Initial Results from

treatment outcomes: a digital solution for remote patient monitoring of stomatitis for patients receiving Dato-DXd

Leveraging novel Dato-DXd resistance models to inform biomarker discovery and rational combinations to

AVANZAR: Phase III Study of Datopotamab Deruxtecan (Dato-DXd) plus Durvalumab plus Carboplatin as 1L

Datopotamab deruxtecan (Dato-DXd) enhances antitumor response to PD-1/PD-L1 inhibitors in TROP2-expressing

LTROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (

TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC

Evaluation of bystander antitumor effect of Dato-DXd in TROP2 (+) and TROP2 (-) lung cell lines admixed

Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple-Negative Breast Cancer (TNBC): Updated Results From

被撤回的出版物: Limbal stem cell deficiency secondary to systemic daptopotamab deruxtecan (Dato-DXd): A case

Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results

Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic

Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results

ORCHARD platform study: Osimertinib plus datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with

Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative

为您找到相关结果约497个

共497条页码: 1/34页15条/页